Website for ESPRIT IL-2 study
17 January 2001. Related: Other news.
Announcing a new Web site with information for participants and health care professionals on the ESPRIT IL-2 study for persons with HIV infection.
ESPRIT is a randomised, international, 5-year, 4000-person study of interleukin-2 (IL-2) in people with HIV infection and a CD4+ cell count of at least 300/mm3. The goal of study is to evaluate and compare the effectiveness of IL-2 plus anti-HIV therapy versus anti-HIV therapy alone on numbers and severity of AIDS-related illnesses and deaths over a 5-year period.